RXR Agonist and Thyroid Hormone Combination for Autoimmune Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for autoimmune diseases using Retinoid X Receptor (RXR) agonists are limited due to activation of Retinoic Acid Receptors (RAR), leading to unwanted side effects and counter-therapeutic inflammatory effects, necessitating a solution that selectively activates RXR without activating RAR.
Innovation Solution
Administering a RXR agonist at a dose that specifically activates RXR, combined with thyroid hormone, to treat autoimmune diseases effectively while minimizing RAR activation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RAR agonists are used to treat autoimmune disorders, then Th17 cell differentiation is inhibited and Treg cell differentiation is enhanced, but pro-inflammatory side effects occur and counter-therapeutic inflammatory effects are observed
Solution Approach 1:
The invention segments the retinoid receptor system into two distinct pathways: RAR agonism for immunosuppressive effects (Th17 inhibition, Treg enhancement) and RXR agonism for anti-inflammatory effects. By using selective RXR agonists rather than pan-retinoid agonists, the therapy separates beneficial immunomodulation from harmful pro-inflammatory side effects, achieving reliable treatment of autoimmune disorders without counter-therapeutic inflammation.
Solution Approach 2:
The invention applies local quality by using selective RXR agonists that specifically activate RXR receptors without activating RAR receptors. This selective activation provides localized immunomodulatory effects (inhibiting Th17, enhancing Treg) at the target site while avoiding the pro-inflammatory effects associated with RAR activation, thereby improving therapeutic reliability without harmful side effects.
2Object-generated harmful factors
If selective RXR agonists are used alone, then anti-inflammatory effects are achieved, but insufficient therapeutic efficacy is observed for autoimmune diseases
Solution Approach 1:
The invention merges two complementary mechanisms: RXR agonism (providing anti-inflammatory effects by inhibiting NF-κB and reducing pro-inflammatory cytokines) and thyroid hormone therapy (enhancing Treg cell function and promoting immune tolerance). This combination achieves both sufficient anti-inflammatory activity and robust therapeutic efficacy for autoimmune diseases, overcoming the limitations of either agent alone.
Solution Approach 2:
The invention creates a composite therapeutic regimen combining selective RXR agonists with thyroid hormones. This composite approach integrates the anti-inflammatory properties of RXR activation with the immunomodulatory effects of thyroid hormones, producing a synergistic effect that achieves both adequate inflammation control and high therapeutic efficacy for autoimmune disorders.
Data Source
AI summary
The present specification provides methods of treating a transplant rejection, pulmonary fibrosis, or glomerulonephritis with a combination of a RXR agonist and a thyroid hormone.